18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: Early experience at sunnybrook health sciences centre

Journal of Otolaryngology - Head and Neck Surgery

Volumn 37, Issue 5, 2008, Pages 712-717

  Dahele, Max ^a   Ung, Yee C ^a,c   Ehrlich, Lisa ^b   Silverberg, Jay ^b   Balogh, Judith ^a   Wong, C Shun ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

18f fluorodeoxyglucose; Positron emission tomography; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; THYROGLOBULIN; BIOLOGICAL MARKER; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PAPILLARY THYROID CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; BLOOD; CANADA; CANCER CENTER; CANCER STAGING; COHORT ANALYSIS; FOLLOW UP; METHODOLOGY; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; THYROIDECTOMY; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; BIOLOGICAL MARKERS; CANCER CARE FACILITIES; CARCINOMA, PAPILLARY; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ONTARIO; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64349093054     PISSN: 19160216     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2008.070189     Document Type: Article

References (24)

1. Sosa JA, Udelsman R. Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol 2006;94:701-7.
2. Holt E. Controversies in the surveillance of patients with well differentiated thyroid cancer. Curr Opin Oncol 2007;19:6-10.
3. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12.
4. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41.
5. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-302.
6. McDougall IR. 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid 1997;7:669-72.
7. Joensuu H, Ahonen A. Imaging ofmetastases ofthyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28:910-4.
8. Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 2006;50:78-87.
9. Hooft L, Hoekstra OS, Deville W, et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:3779-86.
10. Choi MY, Chung JK, Lee HY, et al. The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131I whole body scan: a single-center study of 108 patients. Ann Nucl Med 2006;20:547-52.
11. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxy-glucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
12. Schluter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001;42: 71-6.
13. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616-24.
14. Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging, 2007;34: 487-95.
15. Lind P, Kohlfurst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med 2006;36:194-205.
16. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005;115: 237-43.
17. Shammas A, Degirmenci B, Mountz JM, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer [published erratum appears in J Nucl Med 2007;48:412]. J Nucl Med 2007;48:221-6.
18. 18.Yeo JS, Chung JK, So Y, et al. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 2001;23:94-103.
19. Reinhardt MJ, Wiethoelter N, Matthies A, et al. PET recognition of pulmonary metastases on PET/CT imaging: impact ofattenuation-corrected and non-attenuation-corrected PET images. Eur J Nucl Med Mol Imaging 2006;33:134-9.
20. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001;42:1464-9.
21. Feine U, Lietzenmayer R, Hanke JP, et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37: 1468-72.
22. Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002;37:169-74.
23. Saab G, Driedger AA, Pavlosky W, et al. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid 2006;16:267-72.
24. Petrich T, Borner AR, Otto D, et al. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002;29:641-7.